Autres langues

21/09 Fuso Pharmaceutical Industries,Ltd.(TSE:4538) added to S&P Global BMI Index
10/08 Fuso Pharmaceutical Industries,Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2026
18/05 Fuso Pharmaceutical Industries,Ltd. Reports Earnings Results for the Full Year Ended March 31, 2026
12/05 Fuso Pharmaceutical Industries,Ltd. Provides Non-Consolidated Earnings Guidance for the Six Months Ending September 30, 2026, and Full Fiscal Year Ending March 31, 2027
12/05 Fuso Pharmaceutical Industries,Ltd. Provides Dividend Guidance for the Second Quarter-End Fiscal Year Ending March 31, 2027 and Full Year Ending March 31, 2027
12/05 Fuso Pharmaceutical Industries,Ltd. Proposes Year-End Dividend for the Fiscal Year Ended March 31, 2026, Payable on June 25, 2026
12/05 Fuso Pharmaceutical Industries,Ltd. Announces Board Changes, Effective June 24, 2026
31/03 Fuso Pharmaceutical Industries, Ltd. Concludes Syndicated Loan Agreement
17/02 Fuso Pharmaceutical Industries' Nine-Month Profit Falls 30%; Sales Rise 3%
12/02 Fuso Pharmaceutical Industries,Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2025
10/11 Fuso Pharmaceutical Industries,Ltd. Announces Second Quarter-End Dividend for the Six Months Ended September 30, 2025, Payable on December 2, 2025
05/09/25 Japanese Court Shatters Previous Record For Damages Award In A Patent Infringement Case
01/08/25 Fuso Pharmaceutical Industries, Ltd. Announces Executive Officer Personnel Appointments, Effective September 1, 2025
25/06/25 Fuso Pharmaceutical Industries, Ltd. Announces Executive Changes
09/06/25 Fuso Pharma Appeals 7.47 Billion Yen Patent Ruling to Japan's Supreme Court
04/06/25 Fuso Pharmaceutical Industries Maintains Fiscal 2025 Forecasts Despite Lawsuit
28/05/25 Fuso Pharmaceutical Ordered to Pay 7.47 Billion Yen in Patent Case Over Nalfurafine Tablets
09/05/25 Fuso Pharmaceutical Industries,Ltd. Announces Dividend for Fiscal Year Ended March 31, 2025, Payable on June 26, 2025; Provides Dividend Guidance for the Second Quarter and Fiscal Year Ending March 31, 2026
09/05/25 Fuso Pharmaceutical Industries,Ltd. Provides Non-Consolidated Earnings Guidance for the First Half and Full Fiscal Year Ending March 31, 2026
31/05/24 Fuso Pharmaceutical Industries : Notice of the 101th Annual General Meeting of Shareholders
06/09/23 Tranche Update on Fuso Pharmaceutical Industries,Ltd.'s Equity Buyback Plan announced on September 5, 2023.
06/09/23 Fuso Pharmaceutical Industries,Ltd.'s Equity Buyback announced on September 5, 2023, has closed with
05/09/23 Fuso Pharmaceutical Industries,Ltd. announces an Equity Buyback for 340,000 shares, representing 3.88% for ¥735 million.
05/09/23 Fuso Pharmaceutical Industries,Ltd. authorizes a Buyback Plan.
19/09/22 Fuso Pharmaceutical Industries,Ltd.(TSE:4538) dropped from S&P Global BMI Index
Aucun résultat pour cette recherche